Dai-ichi Life Insurance Company’s Bio-Rad Laboratories Class A BIO Stock Holding History

Dai-ichi Life Insurance Company’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-14,954	Closed	-$8.42M	–	489
2022 Q1	$8.42M	Hold	14,954	–	–	0.13%	150
2021 Q4	$11.3M	Hold	14,954	–	–	0.15%	124
2021 Q3	$11.2M	Sell	14,954 -1,100	-7%	-$824K	0.14%	125
2021 Q2	$10.3M	Buy	16,054 +8,210	+105%	+$5M	0.13%	142
2021 Q1	$4.48M	Sell	7,844 -735	-9%	-$435K	0.06%	220
2020 Q4	$5M	Buy	8,579 +3,057	+55%	+$1.74M	0.07%	198
2020 Q3	$2.85M	Buy	5,522 +1,675	+44%	+$848K	0.05%	259
2020 Q2	$1.74M	Buy	+3,847	New	+$1.7M	0.04%	307

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dai-ichi Life Insurance Company's BIO Position: Q2 2022 in Review

Dai-ichi Life Insurance Company sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2022, closing a stake of 14,954 shares — an estimated $8.42M sold.

Dai-ichi Life Insurance Company first reported a position in BIO in Q2 2020 and held it in 8 quarters. The position peaked at $11.3M in Q4 2021. 501 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

Dai-ichi Life Insurance Company reported no remaining Bio-Rad Laboratories Class A position as of Q2 2022 after selling out during the quarter.
Dai-ichi Life Insurance Company sold 14,954 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $8.42M.
Dai-ichi Life Insurance Company first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 8 quarters.
Dai-ichi Life Insurance Company's Bio-Rad Laboratories Class A position peaked at $11.3M in Q4 2021.
501 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Dai-ichi Life Insurance Company's 13F filing for Q2 2022, filed 12 Aug 2022.